Your browser doesn't support javascript.
loading
Drug Prices and Value of Oncology Drugs in Italy.
Russo, Pierluigi; Marcellusi, Andrea; Zanuzzi, Matteo; Carletto, Angelica; Fratto, Maria Elisabetta; Favato, Giampiero; Staniscia, Tommaso; Romano, Ferdinando.
Afiliación
  • Russo P; Italian Medicines Agency, Rome, Italy; Department of Medicine and Aging Sciences, University of Studies G. d'Annunzio, Chieti-Pescara, Italy.
  • Marcellusi A; Institute for Leadership and Management in Health, Kingston Business School, Kingston University, London, England, UK. Electronic address: a.marcellusi@kingston.ac.uk.
  • Zanuzzi M; Italian Medicines Agency, Rome, Italy.
  • Carletto A; Italian Medicines Agency, Rome, Italy.
  • Fratto ME; Italian Medicines Agency, Rome, Italy.
  • Favato G; Institute for Leadership and Management in Health, Kingston Business School, Kingston University, London, England, UK.
  • Staniscia T; Department of Medicine and Aging Sciences, University of Studies G. d'Annunzio, Chieti-Pescara, Italy.
  • Romano F; Department of Public Health and Infectious Diseases, University La Sapienza, Rome, Italy.
Value Health ; 24(9): 1273-1278, 2021 09.
Article en En | MEDLINE | ID: mdl-34452706
OBJECTIVE: The main objective of this study was to evaluate the potential role of efficacy data and other information available at the time of price and reimbursement (P&R) decision-making process within the definition of oncology treatment costs in Italy. METHODS: The study included all P&R dossiers submitted to the Italian Medicines Agency between July 2015 and December 2017. It prospectively collected the data of the P&R process starting from dossier submission up to the Italian Health Service reimbursement decision. The cost of treatment per patient was estimated using both the list price ("gross cost") and the confidential net price ("net cost") of drug packages and applied to the median duration of treatment. A 2-sample stage Heckman decomposition model was used to evaluate the potential role of efficacy data and other information available at the time of P&R decision making on the gross and net cost. RESULTS: A total of 37 oncology drugs related to 58 therapeutic indications were analyzed. The multivariate model showed that the variation of progression-free survival is the only variable predictor statistically associated with treatment cost, but this effect was observed only when confidential net prices were used (P=.026). CONCLUSIONS: Considering the perspective of a developed country having a public healthcare service with a central reimbursement negotiation is determined a relevant reduction in the treatment cost purchased by public payers. This is a useful approach to guarantee the affordability of innovative oncology drugs and to contain public expenditures on healthcare. Furthermore, the negotiation of confidential discounts and agreement clauses in managed entry agreements seemed to reward oncology drugs displaying an added therapeutic benefit.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Análisis Costo-Beneficio / Oncología Médica / Antineoplásicos Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Análisis Costo-Beneficio / Oncología Médica / Antineoplásicos Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Estados Unidos